Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EIGR Science on IHUB not Twitter.
ECOR ARDS EUA next- ECOR Science at IHUB not Twitter - And Asthma is merely the 1st of Many EUAs coming soon.
HGEN Science At IHUB not Twitter
HGEN Targets Correct COVID Target -GM-CSF - “Itwas reported that the percentages of GM-CSF-expressing CD4+ T cells, CD8+ T cells, natural killer cells and B cells were significantly higher in the blood of patients with COVID-19 who were admitted to an intensive care unit (ICU) than in healthy controls1. This pan-cellular observation was not seen with IL-6 and TNF expression in the respective populations. We, along with others1,72, suggest that in patients with COVID-19, dysregulated GM-CSF expression could induce overactivation of myeloid cells that secrete pro-inflammatory mediators and destructively infiltrate tissue, such as the lungs and potentially even the heart and the nervous system. This suggestion is consistent with the disease-driving mechanism of action of GM-CSF proposed in many preclinical models with pathologies similar to that of late stages of COVID-19” https://www.nature.com/articles/s41577-020-0357-7?elqTrackId=801873428fb148a9b448f36eae558b8b
EIGR Positive Data from Stanford Soon “IFN-? has a decisive function in the respiratory epithelium that greatly limits MERS-CoV replication, and may be a key cytokine for better therapeutic outcomes against MERS-CoV infection in respiratory tract.” https://scholar.google.com/scholar?start=10&q=interferon+lambda&hl=en&as_sdt=0,33&as_ylo=2020#d=gs_qabs&u=%23p%3DG9p7gPGYVVwJ
ECOR for Asthma Just the Start- Vagal Nerve Stimulation Key to Respiratory Disease “Future investigations into vagal neuroscience should also provide for novel therapeutic targets and strategies aimed at reducing the suffering of those inflicted with airway-related pathology.” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982036/
ECOR for PostTraumatic Stress Syndrome - “These findings show that tcVNS has beneficial effects on the underlying neurophysiology of PTSD” https://www.medrxiv.org/content/10.1101/2020.02.10.20021626v3 This is also how Vagal Stimulation relaxes spasm in the respiratory tract in COVID 19. It works.
ECOR Pricing is the NextBig Catalyst - these are limited dosing devices - like a bottle of pills.
Thanks Jay - glad to be here on Ihub.
I appreciate most of my followers on Twitter too - I just can’t tolerate the moderators- So far so good here. I plan do do my posting on Ihub - please let the gang know and follow if you like.
CYDY & HGEN Totally Different Mechanisms of action - CYDY’s loss is HGEN’s gain
BergenBio Bemcentinib # 1 Drug in U.K. COVID19 Accelerated ACCORD Trial (AZN has #2,3) - CEO says it has “an 80% chance of working.” Now 1/2 way till readout it’s being combined with Remdesivir and Decadron,
as an indication it’s working. I’m the only liquidity on the OTC board.
ECOR’s “dawn comes up like thunder outer China 'crost the Bay” New EUA PR in the morning should gain ECOR new attention World Wide- this is not just another mAb from Big Pharma, it’s a new emerging technology with potential broad application from a company that pre EUA had a $32M market cap.
Sorry Tim- I like EIGR and ECOR - I haven’t studied ESPR. Best of luck with it
ECOR -COVID is proof of concept for non COVID Asthma, Autoimmune, and other Pulmonary and nonpulmonary Disease -just a start.
Thanks-here is the full letter from the FDA https://www.fda.gov/media/139967/download
Hey Tim - please find me here - I’m an exTweter- I think ECOR gets premarket PR Monday - Reuters already has the FDA letter online https://www.fda.gov/media/139967/download - so I say it opens 2-3 gets shorted briefly and closes 3-4. In the newer few weeks I expect 5+. The best news is that Vagal stimulus for COVID serves as proof of. Concept for usual asthma, arthritis, and other inflammatory/autoimmune confound - so it has legs.
Best. FEZ
Hey Tim - please find me here - I’m an exTweter- I think ECOR gets premarket PR Monday - Reuters already has the FDA letter online https://www.fda.gov/media/139967/download - so I say it opens 2-3 gets shorted briefly and closes 3-4. In the newer few weeks I expect 5+. The best news is that Vagal stimulus for COVID serves as proof of. Concept for usual asthma, arthritis, and other inflammatory/autoimmune confound - so it has legs.
Best. FEZ
Hey MWM - I got suspended at TWTR and I’m fed up with them -2nd time for no apparent reason. I’m here now - my ECOR wasn’t bad-eh? Hopefully same happens to HGEN EIGR BRRGF. Tell the gang to reach me here - Thanks!
Just because Halozyme hits on every catalyst, it doesnt mean that the funds who own 70% want to pay us more for our 30%-they manipulate the stock so they won't: Roche will- The ADCOM means to Roche that Enhanze will be approved by the FDA in Herceptin SC and Mabthera SC. The higher royalties climb, the greater the offset to the final buyout price. Roche's desire to regain the Avastin indication for Breast cancer is made for pegpH20- to facilitate treatment of this high hyaluronan tumor. The further pegpH20 ph2 trials progress, the higher the price. Severin Schwan said recently he was targeting complementary technologies. There is no more complementary than pegpH20 amd Enhanze.